News from viking therapeutics, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 07, 2016, 07:00 ET Viking Therapeutics to Present at Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...


Sep 01, 2016, 07:30 ET Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...


Jul 26, 2016, 07:03 ET Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...


May 10, 2016, 04:01 ET Viking Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class...


Mar 08, 2016, 04:05 ET Viking Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class...


Feb 02, 2016, 07:30 ET Viking Therapeutics to Present at Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class...


Dec 07, 2015, 07:30 ET Viking Therapeutics Presents New Data on VK5211 Demonstrating Robust Weight Gain in Primates Following 13 Weeks of Treatment

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class...


Nov 17, 2015, 07:30 ET Viking Therapeutics Submits Investigational New Drug (IND) Application to Conduct Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Fatty Liver Disease

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class...


Nov 03, 2015, 07:30 ET Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class...


Oct 20, 2015, 07:30 ET Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator (SARM), in Healthy Elderly Subjects

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class...


Oct 05, 2015, 07:30 ET Viking Therapeutics to Present at Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class...